Peptide LibraryOctreotide dosage in published studies and labels
These are the doses used for Octreotide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Octreotide has FDA-approved human dosages for acromegaly and for the symptoms of carcinoid tumors and VIPomas. Sandostatin injection starts at 50 mcg three times daily under the skin for acromegaly, with 100 mcg three times daily the most common dose; for carcinoid tumors it is 100–600 mcg a day in two to four doses for the first 2 weeks. Sandostatin LAR Depot is 20 mg into the buttock muscle every 4 weeks after a trial of the injection, adjusted to 10–30 mg (up to 40 mg in acromegaly). Mycapssa capsules for acromegaly start at 20 mg twice daily, up to 80 mg a day.
| Human dosing established | Yes |
|---|---|
| Route | Subcutaneous · Intravenous · Intramuscular · Oral |
| Frequency | Two to four times daily (injection); every 4 weeks (LAR Depot); twice daily (capsules) |
| Duration studied | Long-term, adjusted to hormone levels and symptoms |
| Titration | Injection and capsules are adjusted to GH and IGF-1 levels (acromegaly) or symptoms. LAR Depot doses are reviewed after 3 months (acromegaly) or 2 months (carcinoid tumors and VIPomas). |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Sandostatin injection, acromegalyFDA-approved label · FDA prescribing information | Adults with acromegaly who had an inadequate response to, or cannot have, surgery, pituitary irradiation and bromocriptine | Start 50 mcg three times daily; most common dose 100 mcg three times daily; some patients need up to 500 mcg three times daily | Subcutaneous | Three times daily | Long-term; withdrawn yearly for about 4 weeks after irradiation to check disease activity | Lower GH and IGF-1 levels | SANDOSTATIN (octreotide acetate) injection — FDA prescribing information, DailyMed |
| FDA label — Sandostatin injection, carcinoid tumorsFDA-approved label · FDA prescribing information | Adults with metastatic carcinoid tumors with severe diarrhea and flushing | 100–600 mcg a day in two to four divided doses for the first 2 weeks (mean 300 mcg); median maintenance about 450 mcg a day in the label's studies | Subcutaneous | Two to four times daily | — | Control of diarrhea and flushing | SANDOSTATIN (octreotide acetate) injection — FDA prescribing information, DailyMed |
| FDA label — Sandostatin injection, VIPomasFDA-approved label · FDA prescribing information | Adults with VIP-secreting tumors with profuse watery diarrhea | 200–300 mcg a day in two to four divided doses for the first 2 weeks (range 150–750 mcg); usually no more than 450 mcg a day | Subcutaneous | Two to four times daily | — | Control of watery diarrhea | SANDOSTATIN (octreotide acetate) injection — FDA prescribing information, DailyMed |
| FDA label — Sandostatin LAR DepotFDA-approved label · FDA prescribing information | Adults with acromegaly, carcinoid tumors or VIPomas who responded to and tolerated Sandostatin injection | 20 mg every 4 weeks for 3 months (acromegaly) or 2 months (carcinoid tumors, VIPomas), then 10, 20 or 30 mg; up to 40 mg in acromegaly. 10 mg every 4 weeks to start on dialysis or with cirrhosis | Intramuscular, gluteal (never intravenous or subcutaneous) | Every 4 weeks | Long-term maintenance | Long-term control of GH and IGF-1 or of tumor symptoms | SANDOSTATIN LAR DEPOT (octreotide acetate) injectable suspension — FDA prescribing information, DailyMed |
| FDA label — Mycapssa delayed-release capsules, acromegalyFDA-approved label · FDA prescribing information | Adults with acromegaly who responded to and tolerated octreotide or lanreotide | Start 40 mg a day as 20 mg twice daily; increase in 20 mg steps; maximum 80 mg a day. 20 mg once daily to start in end-stage renal disease | Oral, on an empty stomach | Twice daily (once daily at 20 mg in end-stage renal disease) | Long-term maintenance | Maintained IGF-1 control | MYCAPSSA (octreotide) delayed-release capsules — FDA prescribing information, DailyMed |
| FDA label — Bynfezia PenFDA-approved label · FDA prescribing information | Adults with acromegaly, carcinoid tumors or VIPomas (same indications as Sandostatin injection) | Same dosing as Sandostatin injection: acromegaly from 50 mcg three times daily; carcinoid tumors 100–600 mcg a day; VIPomas 200–300 mcg a day | Subcutaneous, prefilled pen | Two to four times daily | — | Lower GH and IGF-1; control of tumor symptoms | BYNFEZIA PEN (octreotide acetate) injection — FDA prescribing information, DailyMed |
Where sources disagree
- Doses differ by form and are not interchangeable: the injection is dosed in micrograms several times a day, the LAR Depot in milligrams every 4 weeks, and the oral capsules in milligrams twice a day.
- Sandostatin LAR Depot is only for patients who first responded to and tolerated the short-acting injection, and it is given into the buttock muscle by a healthcare provider. Mycapssa is only for acromegaly patients already controlled on octreotide or lanreotide.
- The labels warn about gallstones, high or low blood sugar, slow heart rate and conduction changes, and low thyroid function.